Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke.
We defined whether resveratrol administration during the acute phase of ischemic stroke reduces brain injury in mice. Infarct volumes were decreased significantly in both sexes with different doses of resveratrol (5mg/kg for males and 1mg/kg for females) administered 3h after ischemic stroke. Administration of resveratrol 6h after insult was also effective to decrease infarct volumes. Resveratrol suppressed expressions of IL-1β and TNF-α, microglial activation, and ROS production in the ischemic cortex. The findings suggest that the suppression of inflammation is partly associated with the neuroprotective effects of resveratrol, and resveratrol can be developed as a therapeutic drug for acute ischemic stroke.
Shin
Jin A
JA
Department of Pharmacology, Ewha Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Republic of Korea.
Lee
Hyunah
H
Lim
Yoo-Kyoung
YK
Koh
Yaekyu
Y
Choi
Ji Ha
JH
Park
Eun-Mi
EM
D000208:Acute Disease; D000818:Animals; D020520:Brain Infarction / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D002545:Brain Ischemia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D017382:Reactive Oxygen Species / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
D018836:Inflammation Mediators; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; D013267:Stilbenes; D000077185:Resveratrol